Linda Frisk, PharmD, of Arizona Oncology, discusses the role of the pharmacist in new value-based payment models and her experience with the Oncology Care Model (OCM).
Linda Frisk, PharmD, of Arizona Oncology, discusses the role of the pharmacist in new value-based payment models and her experience with the Oncology Care Model (OCM).
What is the role of the oncology pharmacist in new value-based payment models?
I am part of the OCM, so cost of care is important to us, and managing our patients, preventing those side effects from getting worse, interacting with the physician, making sure that what we’re dispensing is the right medicine, the right dose, not auto-filling but checking with the physician, is going to reduce cost of care. It’s going to reduce emergency department visits. It’s going to reduce hospitalization. It’s going to make sure that we don’t dispense a medication that the patient can’t use.
What have been some of the biggest challenges you've had in implementing the Oncology Care Model?
In implementing OCM, there was a lot of a ramp up phase. Oral medications is probably the hardest part, because they don’t all come through us, so it’s a lot of phone calling to patients, to specialty pharmacies, to find out just the basic information that we need to get them enrolled, to get their care plan billed, and to find out where they’re at in their therapy. It would be much easier my sites, because they’re right in the clinics, could dispense the medications, but we know that because of insurance and [pharmacy benefit managers] and things like that, that we can’t dispense all of them. That makes it difficult.
What role does the pharmacist play in implementing clinical pathways?
I’m part of US Oncology McKesson, and we have the value pathways by [National Comprehensive Cancer Network], and they are integrated into our [electronic medical record], so every time that the physicians order a new regimen, they do go through our pathways. And if they don’t follow the pathways, then they have to give a reason why. So, we are very much integrated into that system.
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More